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Background. The main goal of this study was to assess frequency, clinical correlates, and independent predictors of fatigue in a
homogeneous cohort of well-defined glioblastoma patients at baseline prior to combined radio-chemotherapy.
Methods. We prospectively included 65 glioblastoma patients at postsurgical baseline and assessed fatigue, sleepiness, mean
bedtimes, mood disturbances, and clinical characteristics such as clinical performance status, presenting symptomatology, de-
tails on neurosurgical procedure, and tumor location and diameter as well as pharmacological treatment including antiepileptic
drugs, antidepressants, and use of corticosteroids. Data on fatigue and sleepiness were measured with the Fatigue Severity Scale
and the Epworth Sleepiness Scale, respectively, and compared with 130 age- and sex-matched healthy controls.
Results. We observed a significant correlation between fatigue and sleepiness scores in both patients (r¼ 0.26; P¼ .04) and con-
trols (r¼ 0.36; P, .001). Only fatigue appeared to be more common in glioblastoma patients than in healthy controls (48% vs
11%; P, .001) but not the frequency of sleepiness (22% vs 19%; P¼ .43). Female sex was associated with increased fatigue fre-
quency among glioblastoma patients but not among control participants. Multiple linear regression analyses identified depression,
left-sided tumor location, and female sex as strongest associates of baseline fatigue severity.
Conclusions. Our findings indicate that glioblastoma patients are frequently affected by fatigue at baseline, suggesting that fac-
tors other than those related to radio- or chemotherapy have significant impact, particularly depression and tumor localization.
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Glioblastoma is the most common primary brain tumor in
adults, with an estimated incidence of about 3 per 100 000 in-
habitants per year in Europe and North America.1 The standard
of care for newly diagnosed glioblastoma, subsequent to sur-
gery, comprises radiotherapy with concomitant temozolomide
followed by adjuvant temozolomide. In the study defining this
treatment regimen, median survival was limited to 15
months,2 and median survival was reported to be only 12
months in a population-based analysis of more than 10 000
glioblastoma patients.3
Independent of any treatment, fatigue is a common symp-
tom in cancer patients in general as well as in primary brain
tumor patients, with an estimated prevalence of 50%–90%
and 40%–70%, respectively.4,5 Cancer-related fatigue is de-
fined by the National Comprehensive Cancer Network (NCCN)
as a distressing, persistent, subjective sense of physical, emo-
tional, and/or cognitive tiredness or exhaustion related to can-
cer or cancer treatment that is not proportional to recent
activity and interferes with usual functioning.6 The patients
themselves indicate fatigue as one of the most distressing
symptom related to cancer and its treatment.7 It is a strong
predictor of decreased patient satisfaction and health-related
quality of life (QoL) and may represent one of the key reasons
for discontinuing treatment.8 –10 Nevertheless, fatigue is be-
lieved to be underdiagnosed and underestimated in cancer pa-
tients despite its possible impact on treatment compliance.4,11
As a consequence, some groups have questioned whether the
standard treatment for glioblastoma is justified in view of the
limited benefit on survival and the severity of associated
symptoms.12
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Compared with other tumor types, namely breast and lung
cancer, few studies have addressed the problem of fatigue in
glioblastoma patients in depth, and several limitations have
to be mentioned. First, many groups have included patients
with all sorts of primary brain tumors despite large differences
in underlying neurobiology, treatment procedures, and progno-
sis.5,13 Second, baseline data are often missing, particularly in
studies using a cross-sectional design.5 As a consequence, fa-
tigue was mainly assessed as a treatment complication, there-
by failing to acknowledge the primary impact of the tumor
itself and other treatment-independent factors.14 Third, the re-
sults of many older series cannot be directly compared with the
current situation because of advances in radiation techniques.
Finally, while many validated fatigue questionnaires are avail-
able,9,15 the large majority of neuro-oncological studies identi-
fied and quantified fatigue in a very rudimental way, using the
Visual Analogue Scale (VAS) or one single fatigue item appear-
ing in tools such as the European Organisation for Research and
Treatment of Cancer (EORTC) QoL questionnaire, the M DAnder-
son Symptom Inventory–Brain Tumor Module, or the Symptom
Distress Scale.9,12,16–18
Thus, in this prospective study, we aimed at examining fre-
quency and predictors of fatigue severity in a homogeneous
cohort of glioblastoma patients at baseline prior to combined
radio-chemotherapy. For this goal, we used the Fatigue Severity
Scale (FSS), which has been identified as the most widely
adopted fatigue questionnaire in clinical practice and
has been validated for a variety of neurological diseases.15,19,20
In addition, we explored the evolution of fatigue, sleepiness,
and mood disorders during and after combined
radio-chemotherapy.
Patients and Methods
This prospective, longitudinal study was conducted as a collab-
oration of the Departments of Neurology, Oncology, and Radi-
ation Oncology of the University Hospital Zurich between
October 2008 and October 2012. The study protocol was ap-
proved by the Ethics Committee of the Canton of Zurich, Swit-
zerland, specialized subcommittee for Psychiatry, Neurology,
Neurosurgery (Project E-43/2007), and informed consent was
obtained from all patients prior to enrollment.
Participants and Controls
We prospectively included 65 patients with newly diagnosed
and histologically proven glioblastoma, corresponding to an es-
timated 60%–65% of all eligible glioblastoma patients of the
acquisition period. Patients aged≥18 years undergoing postop-
erative standard radio-chemotherapy were eligible.2 They also
had to be fluent in the German language. The participants were
examined clinically and by questionnaires at 3 different time
points: (i) 28+7 days after the initial neurosurgical procedure
(1 day prior to the first radiation), (ii) at the time of the last ra-
diation, and (iii) prior to the initiation of adjuvant chemothera-
py. Overall, the study period captured the first 10 weeks of
postoperative standard treatment.
As control group, we included 130 healthy and age- and sex-
matched individuals using a 1:2 case-control design. The con-
trols were selected from a previously published cohort of 454
healthy subjects that we used in our original validation study
of the German version of the FSS.19
Clinical Assessment and Questionnaires
Demographic variables included age, sex, and educational sta-
tus (defined as highest degree attained). We ascertained sever-
al tumor characteristics including type of neurosurgical
procedure (biopsy, partial, complete or unclear resection),
tumor topography, and brain magnetic resonance imaging-
based tumor diameter. To elucidate whether the presenting
symptomatology affected fatigue severity, we divided the
medical history into seizure, motor weakness, cognitive deficit,
headache/nausea/vomiting, apathy/asthenia, visual deficit,
and accidental finding. Seizure type was further classified as
partial, generalized, complex-focal, and unclassified. To esti-
mate the influence of pharmacological treatment, we included
at each time point details on anticonvulsive drugs, antidepres-
sants, anxiolytics, CNS stimulants, hypnotics, and whether or
not participants received corticosteroids (including the dose
of the steroids). Clinical performance status was assessed by
the Karnofsky performance score (KPS), with 100% indicating
perfect physical health and 0% death. As mentioned earlier,
we measured fatigue by means of the FSS. This self-
administered questionnaire comprises 9 items exploring fa-
tigue severity in different situations during the previous week,
and the final score ranges from 1 to 7 with the latter value in-
dicating maximal fatigue. The presence of clinically significant
fatigue was defined as an FSS score≥4.0. The FSS has robust
psychometric properties and has been validated for various
neurological disorders but has not yet been validated for glio-
blastoma patients. We therefore performed a reliability statistic
in our cohort, which revealed excellent internal consistency as
reflected by a Cronbach’s a of 0.94.21 We used the German ver-
sion of the Epworth Sleepiness Scale (ESS) for assessment of
sleepiness; a score of≥10 indicates excessive daytime sleepi-
ness (EDS).22 We also determined the prevalence of overlap be-
tween fatigue and EDS, when participants presented both a FSS
score≥4.0 and an ESS score≥10. Sleep need was estimated
using information on mean bedtimes. We arbitrarily defined
mean bedtimes≥10 hours as “long bedtimes”, probably indi-
cating increased sleep need per 24 hours (ie, hypersomnia). Fi-
nally, for evaluation of anxiety and depression, we used the
German version of the Hospital Anxiety and Depression Scale
(HADS). It is a well-validated questionnaire, which is suitable
for cancer populations because it contains only nonphysical
symptoms for both anxiety and depression. Subjects indicate
their agreement with each item on a scale ranging from 0 to
3. The questionnaire has 2 subscales for anxiety and depres-
sion, each consisting of 7 items. A score of.10 is considered
to indicate overt anxiety or depression.23,24
Data Analysis and Statistics
We used SPSS (version 19.0) for statistical analysis. Group data
are described by means, standard deviations (SD), and confi-
dence intervals (95% CI). To compare the mean values of FSS
and ESS scores between glioblastoma participants and con-
trols, we used the Student’ t test; the x2 test was used to com-
pare the frequency of fatigue and EDS between the 2 groups.
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Longitudinal differences of scores were assessed using the Stu-
dent’ paired t test. We applied Cronbach a statistics to calculate
the internal consistency of the FSS in glioblastoma patients. To
identify predictors of fatigue severity at baseline, we performed
a multiple linear regression analysis with the FSS score as a de-
pendent variable. Among the set of potential predictor vari-
ables (age, sex, education, KPS, ESS, bedtimes, anxiety and
depression scores, tumor localization, and use of steroids or an-
tidepressants), we evaluated each variable for an estimated ef-
fect of≥0.2 or≤20.2 on the outcome score for fatigue severity
and a P value ,.05 in a univariate comparison. Those predictor
variables fulfilling the 2 criteria were included in the multiple
linear regression model. Significance was accepted at P,.05.
95% confidence intervals (CI) for mean differences between
the groups were additionally presented when group compari-
sons revealed significant differences.
Results
Characterization of Glioblastoma Patients
We included 65 glioblastoma patients, of whom 44 (68%) were
male. Mean agewas 57.3+10.1 years. The tumor was localized
in the left brain hemisphere in 28 patients (43%), in the right
brain hemisphere in 31 patients (48%), and bilateral in 6
patients (9%). A majority of tumors affected the frontotempo-
ral lobes (57%) as compared with the parieto-occipital lobes
(31%), basal ganglia (5%), or multiple sites (8%).
Comparison between Glioblastoma Patients and Controls
Glioblastoma patients had significantly higher FSS scores (3.9+
1.7 vs 2.8+1.0; 95% CI 0,74–1.49; P, .001), fatigue frequency
(48% vs 11%; P, .001), and longer bedtimes (8.8+1.2 h vs
7.7+0.9 h; 95% CI, 0.76–1.39; P, .001) than controls, where-
as ESS scores and the prevalence of EDS were similar (Table 1).
FSS and ESS scores were significantly correlated in both glio-
blastoma patients (r¼ 0.26; P¼ .04) and controls (r¼ 0.36;
P, .001). In glioblastoma patients, overlap of both fatigue
and EDS was observed in 15%, while “isolated fatigue” was
much more common (32%) than “isolated EDS” (6%) (Fig. 1).
Conversely, we observed more controls with isolated EDS
(14%) than isolated fatigue (5%) (P, .001).
Comparison of Glioblastoma Patients With and Without
Fatigue
Almost half of all glioblastoma patients suffered from fatigue
prior to radiotherapy. When compared with those not having
fatigue, glioblastoma patients with fatigue revealed a higher
prevalence of EDS (32% vs 12%; P¼ .04), spent more time in
bed (95% CI, 0.13–1.32; P¼ .02), and were more depressed
(95% CI, 0.78–4.04; P¼.005) (Table 2). In addition, sex distribu-
tion differed significantly: of the 21 female glioblastoma pa-
tients, 14 had fatigue (67%), while only 39% of all male
patients had fatigue (P¼ .03). Of note, fatigue prevalence
was similar in female and male controls (12% vs 10%; P¼
.49). Finally, glioblastoma patients affected by a tumor in the
left brain hemisphere appeared to suffer more frequently
from fatigue than those with right-sided tumors (Table 3). Pa-
tients with left-sided tumor localization were also more prone
to anxiety and depression. On the other hand, we did not ob-
serve any group differences concerning educational status, pre-
senting symptomatology, seizure type, use of antiepileptic
drugs or corticosteroids, or extent of tumor resection.
Predictors of Fatigue Severity in Glioblastoma Patients
Using a multiple linear regression model, we identified higher
HADS depression score (estimated effect¼ 0.16 per 1-unit
Fig. 1. Frequency and overlap of fatigue and excessive daytime sleepiness in glioblastoma patients and controls. In glioblastoma patients, fatigue
is often associated with excessive daytime sleepiness (EDS), but isolated EDS seldom occurs.
Table 1. Comparison of frequency and severity of fatigue, sleepiness,
and mean bedtimes between glioblastoma patients and controls.
Values are mean+standard deviation.
Glioblastoma
Patients (n¼ 65)
Controls
(n¼ 130)
P Value
Age (y) 57.3+10.1 57.4+9.8 .93
Sex, male 44 (68%) 88 (68%) .57
FSS 3.9+1.7 2.8+1.0 <.001
Fatigue (FSS .4.0) 31 (48%) 14 (11%) <.001
ESS 5.9+4.3 6.2+3.6 .67
EDS (ESS. 10) 14 (22%) 25 (19%) .43
Mean bedtime (h) 8.8+1.2 7.7+0.9 <.001
Long bedtime (.10 h) 10 (16%) 4 (3%) .003
Abbreviations: EDS, excessive daytime sleepiness; ESS, Epworth
Sleepiness Scale; FSS, Fatigue Severity Scale; h, hours; y, years.
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Table 2. Comparison of glioblastoma patients with and without fatigue at baseline. Data are described as mean+standard deviation.
Glioblastoma Patients Glioblastoma Patients with Fatigue (n¼ 31) Glioblastoma Patients without Fatigue (n¼ 34) P Value
Age (y) 57.4+10.6 57.2+9.7 .94
Male:female 17 (55%):14 (45%) 27 (79%):7 (21%) .03
KPS 82.2+15.1 85.5+11.3 .36
Tumor diameter (cm) 4.0+1.5 4.0+1.5 .84
Tumor localization .03
Left 19 (61%) 9 (26%)
Right 12 (39%) 19 (56%)
Bilateral 0 6 (18%)
Tumor topography .59
Frontotemporal 20 17
Parieto-occipital 7 13
Basal ganglia 1 2
Frontotemporal+ parieto-occipital 3 1
Parieto-occipital+ basal ganglia 0 1
Presenting symptomatology .18
Seizure 15 15
Motor weakness 5 7
Cognitive deficit 8 7
Headache, nausea, vomiting 8 5
Apathy, asthenia 0 2
Visual deficit 0 3
Accidental finding 0 1
Seizure type .63
No seizure 6 12
Partial 4 5
Generalized 9 8
Complex-focal 2 0
Unclassified 1 1
Partial+ generalized 2 3
Complex-focal+ generalized 0 1
Antiepileptic drugs 19 22 .49
Levetiracetam 9 12
Phenytoin 9 7
Clobazam 5 6
Lamotrigin 2 3
Clonazepam 1 0
Topiramat 1 0
Gabapentin 0 2
Valproat 1 1
Extent of resection .74
Biopsy 2 4
Partial 22 20
Complete 6 8
Unclear 1 2
ESS score 7.1+4.9 4.8+3.4 .03
EDS (ESS score .10) 10 (32%) 4 (12%) .04
Mean bedtime (h) 9.2+1.2 8.5+1.1 .02
Long bedtime (.10 h) 6 (19%) 4 (12%) .25
Anxiety score 6.2+4.0 5.3+3.7 .32
Anxiety, prevalence 7 (23%) 4 (18%) .20
Depression score 5.7+3.5 3.3+3.1 .005
Depression, prevalence 4 (13%) 2 (6%) .29
Corticosteroids [mg] 2.7+3.7 2.5+2.7 .79
Continued
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increase in depression score: P¼ .004), left-sided tumor loca-
tion (estimated effect¼20.88; P¼ .002), and female sex (esti-
mated effect¼ 0.89; P¼ .02) as significant associates of
fatigue severity at baseline prior to radio-chemotherapy
(Table 4). The adjusted r2 and the multiple r2 of our final
model were 0.29 and 0.32, respectively.
Evolution of Fatigue, Excessive Daytime Sleepiness, and
Mood Disorders
Unfortunately, the dropout rate was rather high: only 46 and 38
of the included 65 glioblastoma patients filled out all question-
naires during and after radio-chemotherapy, respectively. Mean
values for FSS and ESS scores, mean bedtimes, mean values for
HADS anxiety and depression scores, and KPS did not show sig-
nificant changes at subsequent time points (Fig. 2).
Discussion
Our prospective study demonstrated that fatigue is a promi-
nent pretreatment symptom in patients with newly diagnosed
and operated glioblastoma, reaching a prevalence of 48% com-
pared with only 11% among healthy controls. Surprisingly, our
data represent the first controlled assessment of fatigue fre-
quency in a selected and homogeneous cohort of glioblastoma
patients that was measured with a specific and validated fa-
tigue questionnaire. Although direct comparison is obviously
hampered by major methodological differences, our finding
roughly matches the reported 40%–70% fatigue prevalence
among patients with primary brain tumors.5,9,14 On the other
hand, we have found higher fatigue prevalence in patients
with other neurological disorders such as multiple sclerosis
(69%), idiopathic Parkinson’s disease (59%), episodic migraine
(54%, unpublished data) or previous ischemic stroke (49%), al-
ways using the FSS.19,20
Fatigue in patients with primary brain tumors has repeatedly
been reported in relation to radiotherapy.13,25,26 In contrast,
our study challenges the view that fatigue in glioblastoma pa-
tients mainly represents a complication of radiotherapy and/or
chemotherapy because the prevalence of fatigue was already
high prior to radio-chemotherapy. Therefore, the contribution
of toxicity from radio-chemotherapy to fatigue is probably
only one factor among many. In addition, the longitudinal as-
sessment of fatigue, sleepiness, and mood disturbances during
and after radio-chemotherapy did not show significant chang-
es, which might however reflect a bias due to the high dropout
rate. It is conceivable, however, that the toxic effect of radio-
chemotherapy on fatigue severity was obscured by the addi-
tional presence of many other fatigue-inducing factors in our
cohort. Of related interest is our observation that pharmacolog-
ical treatment, including antiepileptic drugs, antidepressants or
corticosteroids, was not associated with fatigue. This is in con-
trast to a recent work by Struik et al, who reported an increase
in fatigue severity among patients with low-grade glioma tak-
ing antiepileptic drugs and corticosteroids.27
While fatigue was more than 4 times more prevalent in glio-
blastoma patients than in controls, the frequency of excessive
daytime sleepiness was similar (22% vs 19%). Fatigue and
sleepiness are commonly regarded as 2 distinct symptoms,
but they also present substantial overlap and presumably, at
least to some extent, similar pathophysiology.28 Our finding is
surprising because increased frequency of sleepiness is indeed
common in many neurological disorders with prominent fa-
tigue. For instance, we found excessive daytime sleepiness in
Table 2. Continued
Glioblastoma Patients Glioblastoma Patients with Fatigue (n¼ 31) Glioblastoma Patients without Fatigue (n¼ 34) P Value
Activating antidepressants 3 2 .46
Sedating antidepressants 1 1 .73
Anxiolytics 0 0
CNS stimulants 0 0
Hypnotics 1 2 .54
EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; h, hours; KPS, Karnofsky performance status; y, years.
Table 3. Comparison of fatigue, sleepiness, and mood disorders
between patients with left-sided and right-sided glioblastoma at
baseline prior to radio-chemotherapy. Data are described as mean+
standard deviation.
Left-sided
Tumor
Right-sided
Tumor
P
Value
(n¼ 28) (n¼ 31)
Age (y) 55.8+9.5 57.9+10.5 .43
Male sex 20 (71%) 21 (68%) .60
Karnofsky performance
status
86+14 83+12 .40
Tumor diameter (cm) 4.0+1.7 4.0+1.3 .92
FSS 4.6+1.3 3.5+1.8 .008
Fatigue (FSS .4.0) 19 (68%) 12 (39%) .004
ESS 5.8+4.2 6.0+4.7 .83
EDS (ESS .10) 5 (18%) 8 (26%) .73
Mean bedtime (h) 9.1+1.4 8.6+1.0 .13
Long bedtime (.10 h) 7 (25%) 3 (11) .18
HADS anxiety score 6.6+3.8 5.1+4.0 .16
Anxiety (prevalence) 8 (30%) 3 (10%) .03
HADS depression score 5.3+2.9 3.6+3.8 .05
Depression, prevalence 2 (9%) 4 (13%) .49
EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; FSS,
Fatigue Severity Scale; h, hours; HADS, Hospital Anxiety and Depression
Scale; y, years.
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48% of patients with idiopathic Parkinson’s disease and 38% of
traumatic brain injury survivors, while other groups reported an
even higher prevalence.20,29 Degenerative or trauma-induced
disruption of arousal-promoting structures in the rostral brain-
stem and hypothalamus may cause both fatigue and sleepi-
ness, and this assumption is increasingly supported by
neuropathological evidence.30–32 On the other hand, fatigue
is a complex symptom influenced by a large variety of factors,
and the composition of these contributing factors most likely
differs between neurological disorders commonly associated
with high fatigue burden. Thus, it is tempting to speculate
whether the selective increase of fatigue with normal preva-
lence of sleepiness may shed some light on the underlying eti-
ology of glioblastoma-related fatigue. Of interest in this
context, the discrepant prevalence of fatigue and sleepiness
is reminiscent of patients with mood disorders, who often suf-
fer from fatigue and insomnia, while sleepiness is not a consis-
tent complaint.33 Along the same line, we could identify
depression as an independent predictor of fatigue severity at
baseline by using multiple regression analyses. To the best of
our knowledge, this is the first study to highlight this important
association between fatigue severity and depression in glio-
blastoma patients; similar correlations have been reported in
breast cancer patients but never in patients with primary
brain tumors.34,35
Anxiety and depression represent normal emotional reac-
tions to the diagnosis of glioblastoma, and they are significant
and independent contributors to fatigue severity. However, as
emphasized by the overview of Litofsky and Resnick and further
corroborated by our observations, other factors have to be con-
sidered.36 Of note, fatigue, anxiety and depression all appeared
to be more common in glioblastoma patients with left-sided
tumors compared with those having right-sided tumors; left-
sided tumor location was consistently identified as an indepen-
dent predictor of fatigue severity. Indeed, there is some evi-
dence indicating that patients with left hemispheric lesions
are prone to depressive reactions, whereas patients with right
hemisphere lesions often show indifferent emotional
Table 4. Multiple linear regression model for coefficients of fatigue severity at baseline in glioblastoma patients
Dependent Variable Significant Coefficients* Estimated Effect Standard Error t Value P Value
FSS score (baseline) HADS score for depression 0.16 0.05 3.03 .004
Tumor localization (left) 0.88 0.28 3.16 .002
Female sex 0.89 0.38 2.38 .020
*Additional coefficients included in the model were age, education, Karnofsky performance status, Epworth Sleepiness Scale, bedtimes, Hospital
Anxiety and Depression Scale score for anxiety, use of steroids, and use of antidepressants.
Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale.
Fig. 2. Compared with postsurgical baseline, the scores of the Fatigue Severity Scale (FSS), Epworth Sleepiness Scale (ESS), mean bedtimes, HADS
depression and anxiety, and Karnofsky performance status did not show any significant changes during and immediately after combined
radio-chemotherapy (RCT). Error bars indicate standard deviations.
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reactions.37,38,39 Likewise, Klein et al found significant impair-
ment of attentional and executive functioning in patients
with left-sided high-grade glioma compared with right-sided.40
However, several studies failed to observe any association be-
tween depression and hemispheric laterality of gliomas.41 Data
on depression in ischemic stroke provide a similarly inconsistent
picture. Few studies suggested a higher prevalence of depres-
sion in left-sided ischemic stroke, but other studies could not
confirm a significant impact of stroke location on depressive
symptoms.42 Whether tumor laterality plays such a significant
role in the severity of fatigue, as suggested by our study, re-
mains to be confirmed by future works.
Similar to previous work, we found that female sex was as-
sociated with higher fatigue severity at baseline. Recently, Arm-
strong et al assessed fatigue in 201 patients with primary brain
tumors and demonstrated that moderate-to-severe fatigue
was more common in females, while low fatigue was more
common in males.5
Several limitations of our study have to be acknowledged.
First, the number of participants was relatively small. Second,
dropout rates at subsequent time points were high and might
have introduced significant bias. Our observations on evolution
of fatigue, sleepiness, and mood disorders during and after
radio-chemotherapy must therefore be considered with cau-
tion and require confirmation by larger studies with minimal
dropout rates. However, elimination of a significant dropout
will be challenging, as it is a well-known, notorious problem
in longitudinal studies of primary brain tumor patients. Our
dropout rate was similar, for instance, to that reported in a re-
cent large randomized EORTC trial.43 Third, a certain selection
bias is likely, as we included only 60%–65% of all eligible glio-
blastoma patients during the study period, which prevents di-
rect generalizability of our findings. Finally, we did not
measure the impact of fatigue and associated variables on
health-related QoL.
In summary, roughly half of all glioblastoma patients are af-
fected by fatigue at postsurgical baseline. Depression is among
the strongest predictors of fatigue severity at baseline, which
might also explain the unexpected absence of increased sleepi-
ness in glioblastoma patients. Hence, treating physicians
should be more vigilant for fatigue and depression in glioblas-
toma patients because they both represent frequent comorbid-
ities with mutually negative repercussions and are known to
negatively impact QoL, treatment compliance, and overall
survival.12,16,18,44
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